News | May 30, 2022
Glenmark Pharma reports revenue growth of 5.6% YoY in Q4
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Avacc 3 has significant advantages over existing whooping cough vaccines
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
